You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChloroquine
Accession NumberDB00608  (APRD00468)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionThe prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. [PubChem]
Structure
Thumb
Synonyms
Chloraquine
Chlorochin
Chlorochine
Chloroquina
Chloroquine
Chloroquinium
Chloroquinum
Cloroquina
N(4)-(7-chloro-4-Quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AralenTablet250 mgOralSanofi Synthelabo Canada Inc1951-12-312005-08-01Canada
Teva-chloroquineTablet250 mgOralTeva Canada Limited1968-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ChloroquineTablet, coated500 mg/1OralGolden State Medical Supply, Inc.1999-09-17Not applicableUs
ChloroquineTablet, coated500 mg/1OralPd Rx Pharmaceuticals, Inc.1999-09-17Not applicableUs
ChloroquineTablet250 mg/1OralWest ward Pharmaceutical Corp1975-07-09Not applicableUs
ChloroquineTablet, coated500 mg/1OralCarilion Materials Management1999-09-17Not applicableUs
ChloroquineTablet250 mg/1OralGolden State Medical Supply, Inc.1975-07-09Not applicableUs
ChloroquineTablet, coated500 mg/1OralWest ward Pharmaceutical Corp1999-09-17Not applicableUs
Chloroquine PhosphateTablet250 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.1974-12-112016-11-29Us
Chloroquine PhosphateTablet, film coated250 mg/1Oralbryant ranch prepack2011-03-15Not applicableUs
Chloroquine PhosphateTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.2011-03-15Not applicableUs
Chloroquine PhosphateTablet, film coated250 mg/1OralRanbaxy Pharmaceuticals Inc.2011-03-15Not applicableUs
Chloroquine PhosphateTablet500 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories, Inc.2005-11-012016-11-29Us
Chloroquine PhosphateTablet250 mg/1OralRising Pharmaceuticals, Inc.2011-07-01Not applicableUs
Chloroquine PhosphateTablet, film coated500 mg/1OralRanbaxy Pharmaceuticals Inc.2011-03-15Not applicableUs
Chloroquine PhosphateTablet, film coated500 mg/1Oralbryant ranch prepack2011-03-15Not applicableUs
Chloroquine PhosphateTablet500 mg/1OralRising Pharmaceuticals, Inc.2011-07-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArtrichinNot Available
BemaphateNot Available
CapquinNot Available
MalarexActavis
Nivaquine BSanofi
ResoquineNot Available
ReumachlorNot Available
SanoquinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Chloroquine diphosphate
ThumbNot applicableDBSALT001189
Chloroquine hydrochloride
ThumbNot applicableDBSALT001317
Chloroquine phosphate
Thumb
  • InChI Key: AEUAEICGCMSYCQ-UHFFFAOYNA-N
  • Monoisotopic Mass: 417.15842065
  • Average Mass: 417.867
DBSALT000025
Categories
UNII886U3H6UFF
CAS number54-05-7
WeightAverage: 319.872
Monoisotopic: 319.181525554
Chemical FormulaC18H26ClN3
InChI KeyWHTVZRBIWZFKQO-UHFFFAOYSA-N
InChI
InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
IUPAC Name
7-chloro-N-[5-(diethylamino)pentan-2-yl]quinolin-4-amine
SMILES
CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1
Pharmacology
IndicationFor the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
Structured Indications
PharmacodynamicsChloroquine is the prototype anti malarial drug, most widely used to treat all types of malaria except for disease caused by chloroquine resistant Plasmodium falciparum. It is highly effective against erythrocytic forms of Plasmodium vivax, Plasmodium ovale and Plasmodium malariae, sensitive strains of Plasmodium falciparum and gametocytes of Plasmodium vivax. Being alkaline, the drug reaches high concentration within the food vacuoles of the parasite and raises its pH. It is found to induce rapid clumping of the pigment. Chloroquine inhibits the parasitic enzyme heme polymerase that converts the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. It may also interfere with the biosynthesis of nucleic acids.
Mechanism of actionThe mechanism of plasmodicidal action of chloroquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. nside red blood cells, the malarial parasite must degrade hemoglobin to acquire essential amino acids, which the parasite requires to construct its own protein and for energy metabolism. Digestion is carried out in a vacuole of the parasite cell. During this process, the parasite produces the toxic and soluble molecule heme. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP). To avoid destruction by this molecule, the parasite biocrystallizes heme to form hemozoin, a non-toxic molecule. Hemozoin collects in the digestive vacuole as insoluble crystals. Chloroquine enters the red blood cell, inhabiting parasite cell, and digestive vacuole by simple diffusion. Chloroquine then becomes protonated (to CQ2+), as the digestive vacuole is known to be acidic (pH 4.7); chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further biocrystallization of heme, thus leading to heme buildup. Chloroquine binds to heme (or FP) to form what is known as the FP-Chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-Chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion. In essence, the parasite cell drowns in its own metabolic products.
TargetKindPharmacological actionActionsOrganismUniProt ID
Fe(II)-protoporphyrin IXSmall moleculeyes
antagonist
Plasmodium falciparumnot applicabledetails
Glutathione S-transferase A2ProteinunknownNot AvailableHumanP09210 details
Tumor necrosis factorProteinunknownNot AvailableHumanP01375 details
Toll-like receptor 9ProteinunknownNot AvailableHumanQ9NR96 details
Glutathione S-transferaseProteinunknownNot AvailablePlasmodium falciparumQ8MU52 details
Related Articles
AbsorptionCompletely absorbed from gastrointestinal tract
Volume of distributionNot Available
Protein binding~55% of the drug in the plasma is bound to nondiffusible plasma constituents
Metabolism

Hepatic (partially)

Route of eliminationExcretion of chloroquine is quite slow, but is increased by acidification of the urine.
Half life1-2 months
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Plasmodium
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Chloroquine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Chloroquine is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Chloroquine is combined with 4-Androstenedione.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Chloroquine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Chloroquine is combined with 5-androstenedione.Experimental, Illicit
AbciximabChloroquine may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Chloroquine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Chloroquine.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Chloroquine is combined with Aceclofenac.Approved
AcenocoumarolChloroquine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Chloroquine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Chloroquine.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Acetovanillone.Investigational
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Chloroquine.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Chloroquine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Chloroquine.Approved, Vet Approved
AclarubicinChloroquine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Chloroquine.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chloroquine.Approved
Agalsidase betaThe therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Chloroquine.Approved
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Chloroquine.Approved, Vet Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Alclometasone.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Chloroquine.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Alendronic acid.Approved
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
AliskirenChloroquine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Chloroquine.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Chloroquine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Chloroquine.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Chloroquine.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Chloroquine.Approved, Investigational
Aluminum hydroxideThe serum concentration of Chloroquine can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Chloroquine can be decreased when it is combined with Aluminum phosphate.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Chloroquine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Chloroquine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Amcinonide.Approved
AmikacinChloroquine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideChloroquine may decrease the antihypertensive activities of Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Chloroquine.Approved, Withdrawn
AmiodaroneChloroquine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Chloroquine.Approved
AmodiaquineThe serum concentration of Chloroquine can be decreased when it is combined with Amodiaquine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Chloroquine.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Chloroquine.Approved, Illicit
AmpicillinThe serum concentration of Ampicillin can be decreased when it is combined with Chloroquine.Approved, Vet Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Chloroquine.Approved
AmrubicinChloroquine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Chloroquine.Approved
AnagrelideChloroquine may increase the QTc-prolonging activities of Anagrelide.Approved
AncrodChloroquine may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Chloroquine is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Anisodamine.Investigational
annamycinChloroquine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Chloroquine.Approved
Antithrombin III humanChloroquine may increase the anticoagulant activities of Antithrombin III human.Approved
AnvirzelThe serum concentration of Anvirzel can be increased when it is combined with Chloroquine.Investigational
Aop200704The metabolism of Aop200704 can be decreased when combined with Chloroquine.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Chloroquine.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
ApramycinChloroquine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Chloroquine is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Chloroquine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Chloroquine.Approved
ArbekacinChloroquine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinChloroquine may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArformoterolArformoterol may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
ArgatrobanChloroquine may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Chloroquine.Approved, Investigational
ArotinololThe metabolism of Arotinolol can be decreased when combined with Chloroquine.Approved
ArsenamideThe serum concentration of Arsenamide can be decreased when it is combined with Chloroquine.Vet Approved
Arsenic trioxideChloroquine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Chloroquine.Approved
AsenapineChloroquine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Chloroquine.Approved, Withdrawn
AtazanavirThe metabolism of Chloroquine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Chloroquine.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Chloroquine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Chloroquine.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Azapropazone.Withdrawn
AzelastineThe metabolism of Azelastine can be decreased when combined with Chloroquine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Chloroquine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Chloroquine.Approved
BalsalazideChloroquine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminChloroquine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Beclomethasone dipropionate.Approved, Investigational
BedaquilineChloroquine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololThe metabolism of Befunolol can be decreased when combined with Chloroquine.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Chloroquine.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Chloroquine.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Benoxaprofen.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Chloroquine.Approved
BenzimidazoleThe serum concentration of Benzimidazole can be decreased when it is combined with Chloroquine.Experimental
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Chloroquine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Chloroquine.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Chloroquine.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Chloroquine.Approved, Vet Approved
BetaxololThe metabolism of Chloroquine can be decreased when combined with Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Betulinic Acid.Investigational
BevantololThe metabolism of Bevantolol can be decreased when combined with Chloroquine.Approved
BexaroteneThe serum concentration of Chloroquine can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Chloroquine.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Chloroquine can be decreased when it is combined with Bismuth Subcitrate.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Chloroquine.Approved
BithionolThe serum concentration of Bithionol can be decreased when it is combined with Chloroquine.Withdrawn
BivalirudinChloroquine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Chloroquine.Investigational
BoceprevirThe metabolism of Chloroquine can be decreased when combined with Boceprevir.Approved
BopindololThe metabolism of Bopindolol can be decreased when combined with Chloroquine.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
BosentanThe serum concentration of Chloroquine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chloroquine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chloroquine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Chloroquine.Approved
BromfenacThe risk or severity of adverse effects can be increased when Chloroquine is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Chloroquine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Chloroquine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Bucillamine.Investigational
BucindololThe metabolism of Bucindolol can be decreased when combined with Chloroquine.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Budesonide.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Chloroquine.Experimental, Investigational
BumetanideChloroquine may decrease the diuretic activities of Bumetanide.Approved
BunamidineThe serum concentration of Bunamidine can be decreased when it is combined with Chloroquine.Vet Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Chloroquine.Approved, Investigational
BupranololThe metabolism of Bupranolol can be decreased when combined with Chloroquine.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Chloroquine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Chloroquine can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Chloroquine.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Chloroquine.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Chloroquine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Chloroquine.Approved
Calcium carbonateThe serum concentration of Chloroquine can be decreased when it is combined with Calcium carbonate.Approved
CambendazoleThe serum concentration of Cambendazole can be decreased when it is combined with Chloroquine.Vet Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Chloroquine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Chloroquine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Chloroquine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Chloroquine.Experimental
CaptoprilThe metabolism of Captopril can be decreased when combined with Chloroquine.Approved
CarbamazepineThe metabolism of Chloroquine can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Chloroquine.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Chloroquine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Chloroquine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Chloroquine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Chloroquine.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Chloroquine is combined with Celecoxib.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Chloroquine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Chloroquine.Approved, Vet Approved
CeritinibThe serum concentration of Chloroquine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Chloroquine.Withdrawn
CertoparinChloroquine may increase the anticoagulant activities of Certoparin.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Chloroquine.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Chloroquine.Approved, Illicit
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChloroxylenolThe serum concentration of Chloroxylenol can be decreased when it is combined with Chloroquine.Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Chloroquine.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Chloroquine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Chloroquine.Approved
CholecalciferolThe metabolism of Chloroquine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Chloroquine.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Chloroquine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Chloroquine.Approved
CinacalcetThe metabolism of Chloroquine can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Chloroquine.Approved
CinoxacinChloroquine may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
CisaprideChloroquine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Chloroquine.Approved
CitalopramChloroquine may increase the QTc-prolonging activities of Citalopram.Approved
Citric AcidChloroquine may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinChloroquine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Chloroquine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Chloroquine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Chloroquine.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clodronate.Approved, Investigational, Vet Approved
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Chloroquine.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Chloroquine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clonixin.Approved
ClopidogrelThe metabolism of Chloroquine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Chloroquine.Vet Approved
ClorsulonThe serum concentration of Clorsulon can be decreased when it is combined with Chloroquine.Vet Approved
ClotrimazoleThe metabolism of Chloroquine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Chloroquine.Approved
CobicistatThe serum concentration of Chloroquine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Chloroquine.Approved
CocaineThe metabolism of Chloroquine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Chloroquine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Chloroquine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Chloroquine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chloroquine.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Cortisone acetate.Approved
CoumaphosThe serum concentration of Coumaphos can be decreased when it is combined with Chloroquine.Vet Approved
CrizotinibChloroquine may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Chloroquine is combined with Curcumin.Investigational
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Chloroquine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Chloroquine.Approved, Investigational
CyclosporineChloroquine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Chloroquine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Chloroquine is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chloroquine.Approved
DabrafenibThe serum concentration of Chloroquine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Chloroquine.Approved
DalteparinChloroquine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidChloroquine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Chloroquine.Approved
DapsoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Chloroquine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Chloroquine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Chloroquine.Approved
DasatinibThe serum concentration of Chloroquine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinChloroquine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Chloroquine.Approved
DeferasiroxThe serum concentration of Chloroquine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Chloroquine.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Chloroquine is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Chloroquine can be decreased when combined with Delavirdine.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Chloroquine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Chloroquine.Approved
DesirudinChloroquine may increase the anticoagulant activities of Desirudin.Approved
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Chloroquine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe serum concentration of Chloroquine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Dexamethasone isonicotinate.Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Chloroquine.Approved, Illicit, Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Chloroquine.Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Chloroquine.Approved
DextranChloroquine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Chloroquine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Chloroquine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Chloroquine may increase the anticoagulant activities of Dextran 75.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Chloroquine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Chloroquine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Chloroquine.Approved, Illicit, Vet Approved
DichlorvosThe serum concentration of Dichlorvos can be decreased when it is combined with Chloroquine.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Chloroquine.Approved, Vet Approved
DicoumarolChloroquine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylcarbamazineThe serum concentration of Diethylcarbamazine can be decreased when it is combined with Chloroquine.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chloroquine.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Chloroquine is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Chloroquine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Chloroquine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Chloroquine.Approved, Illicit
DihydroergotamineThe metabolism of Chloroquine can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinChloroquine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Chloroquine.Illicit
DiltiazemThe metabolism of Chloroquine can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Chloroquine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Chloroquine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Chloroquine.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Chloroquine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Chloroquine.Approved
DisopyramideChloroquine may increase the QTc-prolonging activities of Disopyramide.Approved
DithiazanineThe serum concentration of Dithiazanine can be decreased when it is combined with Chloroquine.Vet Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Chloroquine.Approved, Investigational
DofetilideChloroquine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronChloroquine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneChloroquine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Chloroquine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Chloroquine.Approved
DoramectinThe serum concentration of Doramectin can be decreased when it is combined with Chloroquine.Vet Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Chloroquine.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Chloroquine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Chloroquine.Approved, Investigational
DoxorubicinChloroquine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Chloroquine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneChloroquine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
DrospirenoneChloroquine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Chloroquine is combined with Droxicam.Approved
DuloxetineThe metabolism of Chloroquine can be decreased when combined with Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Chloroquine is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Chloroquine is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ebselen.Investigational
Edetic AcidChloroquine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Chloroquine.Approved
EfavirenzThe serum concentration of Chloroquine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Chloroquine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Chloroquine.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Chloroquine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Chloroquine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Chloroquine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Chloroquine.Investigational
EnoxacinChloroquine may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinChloroquine may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Chloroquine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Chloroquine.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Chloroquine is combined with Epirizole.Approved
EpirubicinChloroquine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneChloroquine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Chloroquine.Approved
EprinomectinThe serum concentration of Eprinomectin can be decreased when it is combined with Chloroquine.Vet Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chloroquine.Approved
EquileninThe risk or severity of adverse effects can be increased when Chloroquine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Equilin.Approved
EribulinEribulin may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Chloroquine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
EscitalopramChloroquine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Chloroquine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Chloroquine.Investigational
EsmololThe metabolism of Esmolol can be decreased when combined with Chloroquine.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Chloroquine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Chloroquine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Estrone sulfate.Approved
Etacrynic acidChloroquine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Chloroquine.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chloroquine.Approved
Ethyl biscoumacetateChloroquine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Chloroquine.Approved, Illicit
Etidronic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etofenamate.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Chloroquine.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Chloroquine can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Chloroquine is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Chloroquine.Approved
exisulindThe risk or severity of adverse effects can be increased when Chloroquine is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Chloroquine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Chloroquine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Chloroquine.Approved
FebantelThe serum concentration of Febantel can be decreased when it is combined with Chloroquine.Vet Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Chloroquine.Approved
FelodipineThe metabolism of Chloroquine can be decreased when combined with Felodipine.Approved, Investigational
FenbendazoleThe serum concentration of Fenbendazole can be decreased when it is combined with Chloroquine.Vet Approved
FenbufenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Chloroquine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Chloroquine.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Chloroquine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Chloroquine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Chloroquine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
FlecainideChloroquine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FleroxacinChloroquine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Chloroquine.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Chloroquine is combined with fluasterone.Investigational
FlubendazoleThe serum concentration of Flubendazole can be decreased when it is combined with Chloroquine.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Chloroquine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fludrocortisone.Approved
FluindioneChloroquine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineChloroquine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Chloroquine.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluorometholone.Approved
FluoxetineChloroquine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolChloroquine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Chloroquine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Chloroquine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Chloroquine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Chloroquine.Approved
FluvoxamineThe metabolism of Chloroquine can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Chloroquine.Approved, Nutraceutical, Vet Approved
FondaparinuxChloroquine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumChloroquine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Chloroquine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Formestane.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
FosamprenavirThe metabolism of Chloroquine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Chloroquine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Chloroquine.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Chloroquine.Approved
FosphenytoinThe metabolism of Chloroquine can be increased when combined with Fosphenytoin.Approved
FramycetinChloroquine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideChloroquine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Chloroquine can be increased when it is combined with Fusidic Acid.Approved
GabexateChloroquine may increase the anticoagulant activities of Gabexate.Investigational
Gadobenic acidChloroquine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Chloroquine.Approved
GarenoxacinChloroquine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinChloroquine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Chloroquine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Chloroquine.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Chloroquine.Approved, Withdrawn
GemfibrozilThe metabolism of Chloroquine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinChloroquine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GeneticinChloroquine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinChloroquine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AChloroquine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Chloroquine.Approved
GranisetronChloroquine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Chloroquine.Approved
GrepafloxacinChloroquine may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Chloroquine.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Chloroquine is combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Chloroquine.Approved, Vet Approved
HE3286The risk or severity of adverse effects can be increased when Chloroquine is combined with HE3286.Investigational
HeparinChloroquine may increase the anticoagulant activities of Heparin.Approved, Investigational
HexylresorcinolThe serum concentration of Hexylresorcinol can be decreased when it is combined with Chloroquine.Approved
HigenamineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Higenamine.Investigational
HirulogChloroquine may increase the anticoagulant activities of Hirulog.Experimental
HistrelinHistrelin may increase the QTc-prolonging activities of Chloroquine.Approved
HMPL-004The risk or severity of adverse effects can be increased when Chloroquine is combined with HMPL-004.Investigational
HydralazineChloroquine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Chloroquine.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Chloroquine.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Chloroquine.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Chloroquine.Approved, Illicit
HydroxychloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Chloroquine.Approved
Hygromycin BChloroquine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Chloroquine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Chloroquine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ibuproxam.Withdrawn
IbutilideChloroquine may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe risk or severity of adverse effects can be increased when Chloroquine is combined with Icatibant.Approved
IdarubicinChloroquine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Chloroquine can be increased when it is combined with Idelalisib.Approved
idraparinuxChloroquine may increase the anticoagulant activities of idraparinux.Investigational
IloperidoneChloroquine may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Chloroquine.Approved, Investigational
ImatinibThe metabolism of Chloroquine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Chloroquine.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Chloroquine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Chloroquine.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Chloroquine.Approved
IndenololThe metabolism of Indenolol can be decreased when combined with Chloroquine.Withdrawn
IndinavirThe metabolism of Chloroquine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Chloroquine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Indoprofen.Withdrawn
INNO-206Chloroquine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Chloroquine.Approved
IrbesartanThe metabolism of Chloroquine can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Chloroquine.Approved, Investigational
IsavuconazoniumThe metabolism of Chloroquine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
IsoniazidThe metabolism of Chloroquine can be decreased when combined with Isoniazid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Chloroquine is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Chloroquine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Chloroquine is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Chloroquine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Chloroquine.Approved
IvacaftorThe serum concentration of Chloroquine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Chloroquine.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Chloroquine.Approved
KanamycinChloroquine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KaolinThe serum concentration of Chloroquine can be decreased when it is combined with Kaolin.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Kebuzone.Experimental
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Chloroquine.Approved
KetoconazoleThe metabolism of Chloroquine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Chloroquine.Approved
LabetalolThe metabolism of Labetalol can be decreased when combined with Chloroquine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Chloroquine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Chloroquine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Chloroquine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Chloroquine can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Chloroquine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chloroquine.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Chloroquine.Approved
LenvatinibChloroquine may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinChloroquine may increase the anticoagulant activities of Lepirudin.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
LevamisoleThe serum concentration of Levamisole can be decreased when it is combined with Chloroquine.Vet Approved, Withdrawn
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Chloroquine.Approved, Investigational
LevobunololThe metabolism of Levobunolol can be decreased when combined with Chloroquine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Chloroquine.Approved
LevofloxacinChloroquine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Chloroquine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Chloroquine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Chloroquine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Chloroquine.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Chloroquine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lisofylline.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Chloroquine.Approved
LithiumThe serum concentration of Lithium can be increased when it is combined with Chloroquine.Approved
LomefloxacinChloroquine may increase the neuroexcitatory activities of Lomefloxacin.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Chloroquine.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Chloroquine.Approved
LopinavirChloroquine may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Chloroquine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Chloroquine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lornoxicam.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Chloroquine.Approved
LovastatinThe metabolism of Chloroquine can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Chloroquine.Approved, Investigational
LucanthoneThe serum concentration of Lucanthone can be decreased when it is combined with Chloroquine.Approved, Investigational
LuliconazoleThe serum concentration of Chloroquine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Chloroquine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Chloroquine.Vet Approved
MagaldrateThe serum concentration of Chloroquine can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Magnesium salicylate.Approved
Magnesium TrisilicateThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium Trisilicate.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Chloroquine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Chloroquine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Chloroquine.Approved
ME-609The risk or severity of adverse effects can be increased when Chloroquine is combined with ME-609.Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Chloroquine.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mefenamic acid.Approved
MefloquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mefloquine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Chloroquine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Chloroquine is combined with Meloxicam.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Chloroquine.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Chloroquine.Approved
MesalazineChloroquine may increase the nephrotoxic activities of Mesalazine.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Chloroquine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Chloroquine is combined with Metamizole.Withdrawn
MethadoneMethadone may increase the QTc-prolonging activities of Chloroquine.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Chloroquine.Approved, Illicit
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Chloroquine.Approved
MethotrimeprazineThe metabolism of Chloroquine can be decreased when combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Chloroquine.Approved, Vet Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Chloroquine.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Chloroquine.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Chloroquine.Approved, Investigational
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Chloroquine.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Chloroquine.Approved, Illicit, Withdrawn
MetipranololThe metabolism of Metipranolol can be decreased when combined with Chloroquine.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Chloroquine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Chloroquine.Approved, Investigational
MetrizamideChloroquine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Chloroquine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Chloroquine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Chloroquine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Chloroquine.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
Milbemycin oximeThe serum concentration of Milbemycin oxime can be decreased when it is combined with Chloroquine.Vet Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Chloroquine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Chloroquine.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Chloroquine.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Chloroquine.Approved
MitotaneThe serum concentration of Chloroquine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Chloroquine.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Chloroquine.Approved
ModafinilThe serum concentration of Chloroquine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Chloroquine.Approved
MometasoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mometasone.Approved, Vet Approved
MorantelThe serum concentration of Morantel can be decreased when it is combined with Chloroquine.Vet Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Chloroquine.Approved, Withdrawn
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Chloroquine.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Chloroquine.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be decreased when it is combined with Chloroquine.Vet Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chloroquine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Chloroquine.Approved
NadroparinChloroquine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatChloroquine may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Chloroquine can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Naftifine.Approved
Nalidixic AcidChloroquine may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chloroquine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Chloroquine.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Naproxen.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Chloroquine.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Chloroquine is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Chloroquine is combined with NCX 4016.Investigational
NeamineChloroquine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Chloroquine.Approved, Investigational
NefazodoneThe metabolism of Chloroquine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Chloroquine can be decreased when combined with Nelfinavir.Approved
NemonoxacinChloroquine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinChloroquine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nepafenac.Approved
NetilmicinChloroquine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Chloroquine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Chloroquine can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Chloroquine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Chloroquine.Approved
NiclosamideThe serum concentration of Niclosamide can be decreased when it is combined with Chloroquine.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Chloroquine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Chloroquine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Niflumic Acid.Approved
NilotinibChloroquine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nimesulide.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Chloroquine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Chloroquine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nitroaspirin.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Chloroquine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Chloroquine.Approved
NorfloxacinChloroquine may increase the neuroexcitatory activities of Norfloxacin.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Chloroquine.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
OfloxacinChloroquine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
OlaparibThe metabolism of Chloroquine can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chloroquine.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Chloroquine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Olopatadine.Approved
OlsalazineChloroquine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Chloroquine.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Chloroquine.Approved
OndansetronChloroquine may increase the QTc-prolonging activities of Ondansetron.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Chloroquine can be increased when it is combined with Osimertinib.Approved
OtamixabanChloroquine may increase the anticoagulant activities of Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be increased when it is combined with Chloroquine.Approved
OxamniquineThe serum concentration of Oxamniquine can be decreased when it is combined with Chloroquine.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oxaprozin.Approved
OxfendazoleThe serum concentration of Oxfendazole can be decreased when it is combined with Chloroquine.Vet Approved
OxibendazoleThe serum concentration of Oxibendazole can be decreased when it is combined with Chloroquine.Investigational, Vet Approved
OxprenololThe metabolism of Oxprenolol can be decreased when combined with Chloroquine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Chloroquine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oxyphenbutazone.Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Chloroquine.Approved, Vet Approved
PalbociclibThe serum concentration of Chloroquine can be increased when it is combined with Palbociclib.Approved
PaliperidoneChloroquine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Chloroquine.Approved, Investigational
PamidronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pamidronate.Approved
PanobinostatThe serum concentration of Chloroquine can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Chloroquine is combined with Parecoxib.Approved
ParomomycinChloroquine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe metabolism of Chloroquine can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Chloroquine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chloroquine.Approved
PazufloxacinChloroquine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinChloroquine may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Chloroquine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe metabolism of Penbutolol can be decreased when combined with Chloroquine.Approved, Investigational
PentamidineChloroquine may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe metabolism of Chloroquine can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateChloroquine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Chloroquine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Chloroquine.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Chloroquine.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Chloroquine.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Chloroquine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Chloroquine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Chloroquine.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Chloroquine.Approved, Withdrawn
PhenindioneChloroquine may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Chloroquine can be increased when combined with Phenobarbital.Approved
PhenprocoumonChloroquine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Chloroquine can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Chloroquine.Approved, Investigational
PimozideChloroquine may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Chloroquine.Approved
PioglitazoneThe metabolism of Chloroquine can be decreased when combined with Pioglitazone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Chloroquine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Chloroquine.Approved
PirarubicinChloroquine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideChloroquine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Chloroquine.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Chloroquine.Approved
PlicamycinChloroquine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Chloroquine.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Chloroquine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Chloroquine.Approved
PosaconazoleThe metabolism of Chloroquine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe metabolism of Practolol can be decreased when combined with Chloroquine.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Chloroquine.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Prasterone.Approved, Nutraceutical
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Chloroquine.Approved
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Chloroquine.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Chloroquine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Prednicarbate.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Chloroquine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Chloroquine.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pregnenolone.Experimental
PrilocaineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Prilocaine.Approved
PrimaquineChloroquine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Chloroquine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Chloroquine can be increased when it is combined with Probenecid.Approved
ProcainamideChloroquine may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Chloroquine.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Chloroquine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Chloroquine is combined with Propacetamol.Approved
PropafenoneThe serum concentration of Chloroquine can be increased when it is combined with Propafenone.Approved
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Chloroquine.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Chloroquine.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Chloroquine.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Chloroquine.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Chloroquine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Chloroquine.Vet Approved
Protein CChloroquine may increase the anticoagulant activities of Protein C.Approved
Protein S humanChloroquine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeChloroquine may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Chloroquine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chloroquine.Approved
PrulifloxacinChloroquine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Chloroquine.Approved
PTC299The risk or severity of adverse effects can be increased when Chloroquine is combined with PTC299.Investigational
PuromycinChloroquine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrantelThe serum concentration of Pyrantel can be decreased when it is combined with Chloroquine.Approved, Vet Approved
PyrviniumThe serum concentration of Pyrvinium can be decreased when it is combined with Chloroquine.Approved
QuetiapineChloroquine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Chloroquine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Chloroquine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Chloroquine.Approved
QuinidineChloroquine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineChloroquine may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Chloroquine can be decreased when combined with Rabeprazole.Approved, Investigational
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Chloroquine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Chloroquine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Chloroquine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chloroquine.Approved, Investigational
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Chloroquine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Chloroquine.Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Chloroquine.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Chloroquine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Chloroquine is combined with Resveratrol.Experimental, Investigational
ReviparinChloroquine may increase the anticoagulant activities of Reviparin.Approved
RibostamycinChloroquine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Chloroquine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Chloroquine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Chloroquine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chloroquine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Chloroquine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Risedronate.Approved, Investigational
RisperidoneRisperidone may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
RitonavirThe metabolism of Chloroquine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Chloroquine.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Chloroquine is combined with Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Chloroquine can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Chloroquine.Approved, Investigational
RopiniroleThe metabolism of Chloroquine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Chloroquine.Approved
RosiglitazoneThe metabolism of Chloroquine can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinChloroquine may increase the neuroexcitatory activities of Rosoxacin.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Chloroquine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Chloroquine.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
SalicylamideThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Chloroquine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Chloroquine.Approved
SalsalateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Chloroquine.Experimental
SaquinavirChloroquine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Chloroquine.Investigational
SecobarbitalThe metabolism of Chloroquine can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Chloroquine.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Chloroquine is combined with Seratrodast.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Chloroquine.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Chloroquine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
SildenafilThe metabolism of Chloroquine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chloroquine.Approved
SiltuximabThe serum concentration of Chloroquine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Chloroquine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Chloroquine.Approved
SisomicinChloroquine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Chloroquine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Chloroquine is combined with Sodium Nitrite.Approved
Sodium stibogluconateThe serum concentration of Sodium stibogluconate can be decreased when it is combined with Chloroquine.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Chloroquine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Chloroquine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
SotalolChloroquine may increase the QTc-prolonging activities of Sotalol.Approved
SP1049CChloroquine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinChloroquine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Chloroquine.Experimental
SpectinomycinChloroquine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Chloroquine.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Chloroquine.Approved
SpironolactoneChloroquine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Chloroquine is combined with SRT501.Investigational
St. John's WortThe serum concentration of Chloroquine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Chloroquine can be increased when it is combined with Stiripentol.Approved
StreptomycinChloroquine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinChloroquine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Chloroquine.Approved
SulfasalazineChloroquine may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Chloroquine.Approved
SulodexideChloroquine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Chloroquine.Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Suprofen.Approved, Withdrawn
SuraminThe serum concentration of Suramin can be decreased when it is combined with Chloroquine.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Chloroquine.Approved, Investigational
TacrolimusChloroquine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Chloroquine.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Chloroquine.Approved
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Chloroquine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Chloroquine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Chloroquine.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Chloroquine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Chloroquine.Experimental
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Technetium Tc-99m Medronate.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Chloroquine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Chloroquine.Investigational, Withdrawn
TelaprevirThe metabolism of Chloroquine can be decreased when combined with Telaprevir.Approved
TelavancinChloroquine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinChloroquine may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Chloroquine.Approved, Investigational
TemafloxacinChloroquine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Chloroquine.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Chloroquine.Approved
TenofovirThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Chloroquine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tepoxalin.Vet Approved
TerbinafineThe metabolism of Chloroquine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Chloroquine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Chloroquine.Withdrawn
TeriflunomideThe metabolism of Chloroquine can be decreased when combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Chloroquine.Investigational
TetrabenazineChloroquine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Chloroquine.Approved
ThiabendazoleThe serum concentration of Thiabendazole can be decreased when it is combined with Chloroquine.Approved, Vet Approved
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Chloroquine.Withdrawn
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Chloroquine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Chloroquine.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Chloroquine.Approved
TiclopidineThe metabolism of Chloroquine can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tiludronate.Approved, Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Chloroquine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tinoridine.Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Chloroquine.Approved
TipranavirThe metabolism of Chloroquine can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tixocortol.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Chloroquine.Approved
TobramycinChloroquine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Chloroquine can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Chloroquine.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Chloroquine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chloroquine.Approved, Investigational
TorasemideChloroquine may decrease the diuretic activities of Torasemide.Approved
ToremifeneChloroquine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Chloroquine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chloroquine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Chloroquine.Approved
TranilastThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Chloroquine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Chloroquine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Chloroquine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Chloroquine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Chloroquine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneChloroquine may decrease the antihypertensive activities of Triamterene.Approved
TrichlorfonThe serum concentration of Trichlorfon can be decreased when it is combined with Chloroquine.Vet Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
TriclabendazoleThe serum concentration of Triclabendazole can be decreased when it is combined with Chloroquine.Investigational
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Chloroquine.Approved
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Chloroquine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Trisalicylate-choline.Approved
TrovafloxacinChloroquine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Chloroquine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Chloroquine.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Chloroquine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Chloroquine is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinChloroquine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Chloroquine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Chloroquine.Approved
VandetanibChloroquine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Chloroquine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Chloroquine.Approved
VemurafenibChloroquine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Chloroquine.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Chloroquine.Approved
VerapamilThe metabolism of Chloroquine can be decreased when combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Chloroquine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Chloroquine.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Chloroquine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Chloroquine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Chloroquine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Chloroquine.Approved
VoriconazoleThe metabolism of Chloroquine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Chloroquine.Approved
WarfarinChloroquine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranChloroquine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Chloroquine may increase the anticoagulant activities of Ym150.Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Chloroquine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Chloroquine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Chloroquine.Approved
ZileutonThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneChloroquine may increase the QTc-prolonging activities of Ziprasidone.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zoledronic acid.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Chloroquine.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zomepirac.Withdrawn
ZorubicinChloroquine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZuclopenthixolChloroquine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation and increase bioavailability.
References
Synthesis Reference

Andersag, H., Breitner, S.and Jung, H.; U S . Patent 2,233,970; March 4,1941; assigned to
Winthrop Chemical Company, Inc.

US2233970
General ReferencesNot Available
External Links
ATC CodesP01BA01
AHFS Codes
  • 08:30.08
PDB Entries
FDA labelDownload (153 KB)
MSDSDownload (74.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9939
Blood Brain Barrier+0.7421
Caco-2 permeable+0.5804
P-glycoprotein substrateSubstrate0.8
P-glycoprotein inhibitor IInhibitor0.622
P-glycoprotein inhibitor IIInhibitor0.7773
Renal organic cation transporterInhibitor0.6046
CYP450 2C9 substrateNon-substrate0.8422
CYP450 2D6 substrateSubstrate0.8804
CYP450 3A4 substrateSubstrate0.6009
CYP450 1A2 substrateNon-inhibitor0.8586
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9218
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5496
Ames testAMES toxic0.9106
CarcinogenicityNon-carcinogens0.8374
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9547 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6959
hERG inhibition (predictor II)Inhibitor0.8293
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Impax laboratories inc
  • Ipca laboratories ltd
  • Md pharmaceutical inc
  • Purepac pharmaceutical co
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedOral500 mg/1
TabletOral250 mg/1
TabletOral500 mg/1
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
TabletOral250 mg
Prices
Unit descriptionCostUnit
Aralen 500 mg tablet7.85USD tablet
Aralen phosphate 500 mg tablet7.78USD tablet
Chloroquine ph 500 mg tablet5.64USD tablet
Chloroquine Phosphate 500 mg tablet5.42USD tablet
Chloroquine phosphate powdr4.29USD g
Plaquenil 200 mg tablet3.14USD tablet
Chloroquine Phosphate 250 mg tablet2.57USD tablet
Chloroquine ph 250 mg tablet2.49USD tablet
Novo-Chloroquine 250 mg Tablet0.35USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility10.6 mg/LNot Available
logP4.63HANSCH,C ET AL. (1995)
pKa10.1SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0175 mg/mLALOGPS
logP5.28ALOGPS
logP3.93ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)10.32ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area28.16 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity96.42 m3·mol-1ChemAxon
Polarizability37.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.47 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-000i-9320000000-2663c398ede2e502ca34View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminoquinolines and derivatives. These are organic compounds containing an amino group attached to a quinoline ring system.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassAminoquinolines and derivatives
Direct ParentAminoquinolines and derivatives
Alternative Parents
Substituents
  • Chloroquinoline
  • Aminoquinoline
  • Secondary aliphatic/aromatic amine
  • Aminopyridine
  • Benzenoid
  • Pyridine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

1. Fe(II)-protoporphyrin IX
Kind
Small molecule
Organism
Plasmodium falciparum
Pharmacological action
yes
Actions
antagonist
References
  1. Fitch CD: Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 2004 Mar 5;74(16):1957-72. [PubMed:14967191 ]
  2. Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG: An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol. 1998 Mar 15;55(6):727-36. [PubMed:9586944 ]
  3. Stoller TJ, Shields D: The propeptide of preprosomatostatin mediates intracellular transport and secretion of alpha-globin from mammalian cells. J Cell Biol. 1989 May;108(5):1647-55. [PubMed:2565905 ]
  4. Mockenhaupt FP, May J, Bergqvist Y, Meyer CG, Falusi AG, Bienzle U: Evidence for a reduced effect of chloroquine against Plasmodium falciparum in alpha-thalassaemic children. Trop Med Int Health. 2001 Feb;6(2):102-7. [PubMed:11251905 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Glutathione transferase activity
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name:
GSTA2
Uniprot ID:
P09210
Molecular Weight:
25663.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
References
  1. Jang CH, Choi JH, Byun MS, Jue DM: Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford). 2006 Jun;45(6):703-10. Epub 2006 Jan 17. [PubMed:16418198 ]
  2. Rachmilewitz D, Karmeli F, Shteingart S, Lee J, Takabayashi K, Raz E: Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis. Inflamm Bowel Dis. 2006 May;12(5):339-45. [PubMed:16670522 ]
  3. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A: Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus. 2006;15(5):268-75. [PubMed:16761500 ]
  4. Lim EJ, Lee SH, Lee JG, Chin BR, Bae YS, Kim JR, Lee CH, Baek SH: Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling. FEBS Lett. 2006 Aug 7;580(18):4533-8. Epub 2006 Jul 17. [PubMed:16870179 ]
  5. Dias-Melicio LA, Calvi SA, Bordon AP, Golim MA, Peracoli MT, Soares AM: Chloroquine is therapeutic in murine experimental model of paracoccidioidomycosis. FEMS Immunol Med Microbiol. 2007 Jun;50(1):133-43. Epub 2007 Apr 23. [PubMed:17456179 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transmembrane signaling receptor activity
Specific Function:
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the i...
Gene Name:
TLR9
Uniprot ID:
Q9NR96
Molecular Weight:
115858.665 Da
References
  1. Trevani AS, Chorny A, Salamone G, Vermeulen M, Gamberale R, Schettini J, Raiden S, Geffner J: Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol. 2003 Nov;33(11):3164-74. [PubMed:14579285 ]
  2. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol. 2004 Sep;34(9):2541-50. [PubMed:15307186 ]
  3. Lenert P: Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol. 2005 Apr;140(1):1-10. [PubMed:15762869 ]
  4. Huang LY, Ishii KJ, Akira S, Aliberti J, Golding B: Th1-like cytokine induction by heat-killed Brucella abortus is dependent on triggering of TLR9. J Immunol. 2005 Sep 15;175(6):3964-70. [PubMed:16148144 ]
  5. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006 Jul;4(7):437-47. [PubMed:16849519 ]
Kind
Protein
Organism
Plasmodium falciparum
Pharmacological action
unknown
General Function:
Glutathione transferase activity
Specific Function:
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. May also function as a storage protein or ligandin for parasitotoxic ferriprotoporphyrin IX (hemin).
Gene Name:
GST
Uniprot ID:
Q8MU52
Molecular Weight:
24788.9 Da
References
  1. Hiller N, Fritz-Wolf K, Deponte M, Wende W, Zimmermann H, Becker K: Plasmodium falciparum glutathione S-transferase--structural and mechanistic studies on ligand binding and enzyme inhibition. Protein Sci. 2006 Feb;15(2):281-9. Epub 2005 Dec 29. [PubMed:16385005 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23